PP
DSGN icon

PDT Partners’s Design Therapeutics DSGN Stock Holding History

PDT Partners’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-36,099
Closed -$223K – 773
2024
Q4 		$223K Hold
36,099
– – 0.02% 638
2024
Q3 		$194K Buy
36,099
+8,972
+33% +$42.2K 0.02% 663
2024
Q2 		$90.9K Buy
+27,127
New +$106K 0.01% 644
2024
Q1 		– Sell
-28,401
Closed -$75.3K – 642
2023
Q4 		$75.3K Sell
28,401
-5,281
-16% -$12.1K 0.01% 523
2023
Q3 		$79.5K Sell
33,682
-13,830
-29% -$64.5K 0.01% 560
2023
Q2 		$299K Sell
47,512
-12,457
-21% -$76.2K 0.04% 454
2023
Q1 		$346K Buy
+59,969
New +$449K 0.05% 437

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PDT Partners's DSGN Position: Q1 2025 in Review

PDT Partners sold out of Design Therapeutics (DSGN) in Q1 2025, closing a stake of 36,099 shares — an estimated $223K sold.

PDT Partners first reported a position in DSGN in Q1 2023 and held it in 7 quarters. The position peaked at $346K in Q1 2023. 98 funds tracked by Wall St. Rank hold DSGN as of Q1 2025.

  • PDT Partners reported no remaining Design Therapeutics position as of Q1 2025 after selling out during the quarter.
  • PDT Partners sold 36,099 Design Therapeutics shares in Q1 2025, an estimated $223K.
  • PDT Partners first reported a position in Design Therapeutics in Q1 2023 and held it in 7 quarters.
  • PDT Partners's Design Therapeutics position peaked at $346K in Q1 2023.
  • 98 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2025.

Based on PDT Partners's 13F filing for Q1 2025, filed 15 May 2025.